226950 — OliX Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- KR₩3tn
- KR₩3tn
- KR₩15bn
Brief: OliX And Lilly Enter Global Licensing Agreement For Mash And Other Cardiometabolic Indications
Brief: Olix Pharmaceuticals Commences Patient Dosing In Phase 1 Clinical Trial Of Olx75016
Brief: Olix Pharmaceuticals Receives Hrec Approval To Initiate Phase 1 Clinical Trial Of Nash And Obesity Drug
Brief: OliX Pharmaceuticals Administers First Patient In Phase 1 Clinical Study of Androgenic Alopecia Treatment
Brief: Olix Pharmaceuticals Announces Results From Phase 2A Trial Of OLX10010
Brief: OliX Pharmaceuticals Doses First Patient In Clinical Trial For RNAi Therapeutic OLX10212 For Dry And Wet Age-Related Macular Degeneration
Brief: Olix Pharmaceuticals Receives Regulatory Approval To Commence Phase 1 Clinical Trial Of Treatment Of Androgenic Alopecia
Brief: Olix Pharmaceuticals Inc To Invest 13 Billion Won In Research And Development Centre And Headquarters Construction
Brief: Olix Pharmaceuticals Publishes Preclinical Research Demonstrating Olx104c’S Potential As An Effective Treatment For Hair Loss
Brief: Olix Pharmaceuticals Announces Positive Preclinical Data In NASH Non-Human Primate Models
Brief: Olix Pharmaceuticals Announces Ind Submission To U.S. FDA To Evaluate Safety And Tolerability Of Olx10212 In Phase 1 Clinical Trial
Brief: Olix Pharmaceuticals Announces Completion Of Enrollment In Phase 2 Clinical Trial Of Olx101a In Patients With Hypertrophic Scars
Brief: Olix Pharmaceuticals Identifies Effective Inhibition Of Target Gene Expression
Brief: Olix Pharmaceuticals Subsidiary mCureX Strengthens Scientific Advisory Board With Appointment Of Nucleic Acid Therapeutics And Immunology Specialist Dr. Gunther Hartmann
Brief: OliX Enters Agreement With Pharmaron To Advance Non-Clinical Toxicology Testing For Hepatitis B Candidate OlX703A
Brief: Hansoh Pharma And Olix Pharmaceuticals Enter Into Licensing And Collaboration Agreement
Brief: Hansoh Pharmaceutical Says Units Entered Into Exclusive License And Collaboration Agreement With OliX Pharmaceuticals
Brief: OliX Pharmaceuticals Says Received Notice Of Allowance From U.S. Patent And Trademark Office For OLX104C
Brief: Olix Pharmaceuticals Subsidiary Mcurex Announces Agreements To Advance Development Of MRNA Vaccines And Therapeutics